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Abstract Lactic acid bacteria (LAB) constitute a hetero-
geneous group of microorganisms that produce lactic ac-
id as the major product during the fermentation process.
LAB are Gram-positive bacteria with great biotechnolog-
ical potential in the food industry. They can produce
bacteriocins, which are proteinaceous antimicrobial mol-
ecules with a diverse genetic origin, posttranslationally
modified or not, that can help the producer organism to
outcompete other bacterial species. In this review, we
focus on the various types of bacteriocins that can be
found in LAB and the organization and regulation of
the gene clusters responsible for their production and
biosynthesis, and consider the food applications of the
prototype bacteriocins from LAB. Furthermore, we pro-
pose a revised classification of bacteriocins that can ac-
commodate the increasing number of classes reported
over the last years.
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Introduction
The production of antagonistic substances by living organisms
is a conserved characteristic throughout evolution, constitut-
ing an effective ancestral defense mechanism. Bacteriocins are
ribosomally produced antimicrobial peptides from bacteria,
either processed or not by additional posttranslational modifi-
cation (PTM) enzymes, and exported to the extracellular me-
dium (Cotter et al. 2005).
Bacteriocins produced by lactic acid bacteria (LAB) are
particularly interesting due to the long history of safe use of
some of them and the generally regarded as safe (GRAS) and
Qualified Presumption of Safety (QPS) status that most LAB
possess. LAB are a heterogeneous group of Gram-positive
fermentative bacteria belonging to Firmicutes that encom-
passes various genera (Table 1) (Carr et al. 2002). Although
bifidobacteria are not strictly LAB, they have been tradition-
ally studied together and will also be considered in this review.
We aim to provide an overview of the prevalence of bacte-
riocin classes in LAB. We highlight the classes that have been
described in LAB providing examples of the most relevant
cases for each class paying attention to the genetics, structure,
and mechanism of action. Moreover, we discuss some bacte-
riocin groups that can be detected in silico in publicly avail-
able LAB genomes even though no representative from a
LAB has yet been reported. Due to their biotechnological
interest, the application of some bacteriocins in food process-
ing is briefly described.
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Classification of bacteriocins from lactic acid
bacteria
There are a large number of bacteriocins isolated from nature.
Some databases have been created to compile this information
(e.g., van Heel et al. 2013). In addition to published bacterio-
cins, the repertoire of molecules hidden in the genomes that
have not been isolated yet represents a valuable source of
novel compounds with great potential. Diverse tools have
been created that can be used for the automated screening of
bacteriocin gene clusters (Blin et al. 2013; van Heel et al.
2013). A total of 238 complete LAB genomes deposited in
public databases and belonging to the genera indicated in
Table 1 were analyzed using Bagel3. This search resulted in
a list of 785 putative bacteriocin gene clusters, including
ribosomally produced and posttranslationally modified peptides
(RiPPs) that were not previously identified in LAB. In this list,
we could observe previously characterized bacteriocins or natural
variants, some of them spread among different species, and new
putative bacteriocins with no significant homology to known
peptides based on the blast results provided (Table S1).
Since the first classification of LAB bacteriocins, proposed
by Klaenhammer (1993), different schemes have been pro-
posed taking it as a basis. New RiPP subgroups with antimi-
crobial activity produced by bacteria have been discovered
that do not fit in either classification in spite of fitting in the
definition of bacteriocin. We propose a slightly adjusted clas-
sification for LAB that can accommodate the novel subclasses
that are appearing, based on the biosynthesis mechanism and
biological activity, which is in acoordance with previous pro-
posals (Cotter et al. 2013; Arnison 2013). Although we focus
on bacteriocins fromLAB, this scheme is also valid for known
compounds from other microorganisms (Fig. 1).
Class I: RiPPs (less than 10 kDa) This class encompasses all
the peptides that undergo enzymatic modification during bio-
synthesis, which provides molecules with uncommon amino
acids and structures that have an impact on their properties
(e.g., lanthionine, heterocycles, head-to-tail cyclization, gly-
cosylation). They consist of a leader peptide which serves for
enzyme recognition, transport, and keeping the peptide inac-
tive, which is fused to a core peptide (Arnison et al. 2013). The
key signatures for an appropriate and systematic definition of
novel members of this class have been recently suggested
(Medema et al. 2015). Other RiPP subclasses not found in
LAB are not further discussed here (for a review see
Arnison et al. 2013).
Class II: unmodified bacteriocins (less than 10 kDa) This
class groups bacteriocins that do not contain unusual modifi-
cations. Thus, they do not require enzymes for their matura-
tion other than a leader peptidase and/or a transporter.
Class III These are unmodified bacteriocins larger than
10 kDa with bacteriolytic or non-lytic mechanism of action.
Class I: small posttranslationally modified peptides
Class Ia. Or lanthipeptides (types I, II, III, and IV)
Lanthipeptides are peptides possessing unusual amino acids,
such as lanthionine and/or (methyl)lanthionine (Arnison et al.
2013). Lanthipeptides undergo PTMs, and generally the genes
involved in the maturation process are located in the same
operon. Based on the PTM enzymes involved in the matura-
tion process, lanthipeptides can be divided into four types, but
Table 1 Number of putative bacteriocin gene cluster identified in 238 complete genomes
Genera Class I Class II Class III Total
Lanthipeptide I Lanthipeptide II Cyclic peptide Sactipeptide Glycocin Lasso peptide LAP
Aerococcus (1) 0
Bifidobacterium (31) 2 2 4
Carnobacterium (3) 1 6 1 8
Enterococcus (12) 3 1 1 13 7 25
Lactobacillus (59) 16 23 3 86 76 204
Lactococcus (13) 3 7 1 20 1 32
Leuconostoc (8) 1 6 7
Oenococcus (1) 1 1
Pediococcus (3) 1 2 3
Streptococcus (105) 16 22 15 7 5 4 33 388 10 500
Tetragenococcus (1) 1 1
Weisella (1) 0
TOTAL 19 29 41 15 29 4 37 514 97 785
Numbers in parentheses () indicate the number of genomes analyzed per genus
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only types I (LanBC-modified) and II (LanM-modified) can
be considered lantibiotics (Knerr and van der Donk 2012).
Types III and IV have no known antimicrobial activity and
are not further considered here.
A great number of different lantibiotics are produced
by LAB (Table 1). Among them, nisin, a type I lantibiotic
produced by Lactococcus lactis, is the best studied. The
nisin biosynthetic gene cluster consists of 11 genes
(Fig. 2). Promoters transcribing the nisABTCIP (biosyn-
thesis and immunity) and nisFEG (immunity) operons are
controlled by the two-component system NisRK that re-
sponds to the nisin concentration in a typical quorum
sensing (QS) system (Lubelski et al. 2008). This QS
mechanism has been also shown for type II lantibiotics
such as bovicin HJ50 (Ni et al. 2011).
Lantibiotic maturation is a process encompassing sever-
al enzymatic reactions. The nisin precursor is modified by
the dehydratase NisB which dehydrates Ser and Thr via
glutamyl-tRNA-dependent glutamylation and elimination
(Garg et al. 2013; Ortega et al. 2015). The cyclase NisC
promotes the reversible Michael-type nucleophilic attack
from the thiol group of a cysteine to an N-terminal-
l o c a t e d d e h y d r a t e d r e s i d u e r e n d e r i n g t h e
(methyl)lanthionine rings (Lubelski et al. 2008; Yang and
van der Donk 2015). Subsequently, the fully modified pre-
cursor is transported (NisT) and proteolytically activated
(NisP) (Lubelski et al. 2008). For some type I lantibiotics,
this step is performed most likely intracellularly (e.g.,
Pep5) or even by an unknown leader peptidase not associ-
ated to the lantibiotic cluster (e.g., subtilin) (Knerr and van
der Donk 2012). In type II lantibiotics, the processes of
dehydration and cyclization are carried out by a bifunction-
al LanM enzyme that performs the phosphorylation-
elimination reaction on the dehydratable residues and
forms the rings (Knerr and van der Donk 2012). Lacticin
3147 from L. lactis is one of the best-studied type II
lantibiotics. It consists of two peptides, LtnA1 and
LtnA2, which are processed by LtnM1 and LtnM2, respec-
tively. Finally, the bifunctional enzyme LtnT removes the
leader peptide and translocates the modified peptides
(Suda et al. 2012). Recently, the role of the leader peptide
of lantibiotics as an activator of the PTM enzymes has been
revealed (Oman et al. 2012). Apart from lanthionine rings
and dehydrated residues, other modified amino acids have
been detected in lantibiotics (Knerr and van der Donk

































Fig. 1 Proposed classification
scheme for bacteriocins and their
structures. Classes identified in
silico are depicted in gray.
Structure of non-lytic bacteriocins
of class III still remains
uncharacterized. *Bacteriocins
from non-lactic acid bacteria
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The mechanism of action of most lantibiotics relies on
lipid II binding. Nisin inhibits its target removing lipid II
from its natural location and subsequent insertion into the
cell membrane to form a pore (Breukink et al. 1999;
Hasper et al. 2006; Lubelski et al. 2008). Lacticin 3147
also targets lipid II, and a three-step model has been pro-
posed where the α-peptide binds to lipid II, then it is rec-
ognized by the β-peptide which inserts into the membrane
and forms a pore (Wiedeman et al. 2006; Suda et al. 2012).
It has been reported that other type II lantibiotics lack the
ability to form pores after interaction with lipid II via a
specific binding pocket (Islam et al. 2012), but can strong-
ly induce a cell stress response (Sass et al. 2008). The pore-
forming ability of some lantibiotics is compromised by the
membrane composition and thickness of the sensitive
strain (Wiedeman et al. 2006).
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Fig. 2 Schematic representation
of bacteriocin gene clusters (not
drawn to scale). Black, structural
genes; dark gray, transporter
genes; light gray, modification
and maturation genes; bars,
immunity genes; white, others.
*Bacteriocins from non-lactic
acid bacteria
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Class Ib. Or head-to-tail cyclized peptides
Head-to-tail cyclized bacteriocins are a group of RiPPs whose
N- and C-termini are linked by a peptide bond, thereby
rendering a circular molecule (Fig. 1). All of them contain
only alpha helical segments (either 4 or 5) and share a
similar structure with a saposin folding (Montalbán-López
et al. 2012a; Lohans et al. 2013; Acedo et al. 2015; Himeno
et al. 2015).
In spite of their similar structure, two different mechanisms
of action are shown for circular bacteriocins, both involving
pore formation. In the case of carnocyclin A, it is able to form
pores in bacterial membranes in a voltage-dependent manner
(Gong et al. 2009). Multimers of carnocyclin A are not found
in solution (Martin-Visscher et al. 2009). On the other hand,
AS-48 forms dimers in aqueous solution which rearrange in
the membrane to bury the hydrophobic core in the lipid bilayer
(Cruz et al. 2013; Cebrián et al. 2015). Studies with garvicin
ML show that the expression of a maltose-binding protein in
L. lactis increases the sensitivity to this bacteriocin
(Gabrielsen et al. 2012). This constitutes the first report on a
putative target for a circular bacteriocin, although its exact role
remains to be demonstrated.
The gene cluster of AS-48 is formed by 10 genes including
as-48Awhich codes for the structural gene, as-48B for a pu-
tative cyclase, as-48C for a DUF95 protein related to immu-
nity and production (Mu et al. 2014), as-48C1D for a putative
ABC transporter related to production, as-48D1 for a typical
immunity protein, and as-48EFGH for an additional ABC
transporter which is immunity related (Fig. 2) (Maqueda
et al. 2008). The minimal set for the functional expression of
the circular bacteriocin circularin has been determined as
cirABCDE (equivalent to as-48ABCDD1) (Maqueda et al.
2008). The transporter As-48EFGH is not present in some of
the known gene clusters indicating that it has a minor role for
production and it is related only to immunity (Maqueda et al.
2008; Gabrielsen et al. 2014a). No gene encoding for a puta-
tive regulator has been found in the LAB circular bacteriocins
described, the only exception being a putative circular bacte-
riocin cluster detected in silico in Streptococcus pneumoniae
that contains a putative regulator upstream the structural gene
(Maqueda et al. 2008; Bogaardt et al. 2015). The expression of
AS-48 requires the expression of a large transcript that encom-
passes as-48ABC which is posttranscriptionally processed, a
second transcript including as-48C1DD1EFGH, and a third
transcript from a weak promoter that transcribes as-
48D1EFGH (Sánchez-Hidalgo et al. 2011; Cebrián et al.
2014). The typical organization, where the expression of the
structural gene is paired to the expression of the immunity and
the maturation machinery, is not present in the garvicin ML
gene cluster (Gabrielsen et al. 2014b).
The fact that there is not a C-terminal extension in circular
bacteriocins as in the case of cyclotides or cyanobactins and
that the leader peptide seems to be cleaved off in a separate
step could indicate that the cyclization takes place during
transport involving the ATPase activity to provide the energy
necessary for the peptide bond formation (Montalbán-López
et al. 2012a; Craik and Malik 2013; Gabrielsen et al. 2014a;
Scholz et al. 2014).
Class Ic. Or sactibiotics
Sactipeptides (also referred to as sactibiotics when they pos-
sess antimicrobial activity) are sulphur-to-α-carbon-
containing peptides (Arnison et al. 2013; Mathur et al.
2015). To the best of our knowledge, there has been no
sactipeptide from a LAB characterized so far and only puta-
tive clusters have been identified in silico (Table 1) (Table S1)
(Murphy et al. 2011), awaiting further study.
They show great diversity, with the hairpin structure and
the sulfur linkages being the common feature. The best stud-
ied, subtilosin A, is a negatively charged circular sactipeptide
produced by Bacillus subtilis (Fig. 1) (Kawulka et al. 2003;
Maqueda et al. 2008). It exhibits 3S-to-α-carbon bonds and
displays a broad spectrum activity against diverse bacteria
(Montalbán-López et al. 2011; Mathur et al. 2015). Thuricin
CD is a narrow-spectrum two-component linear sactibiotic
produced by Bacillus thuringiensis with potent activity
against Clostridium difficile (Rea et al. 2010). Thurincin H,
also produced by B. thuringiensis, is a single peptide with 4S-
to-α-carbon bonds (Mathur et al. 2015).
No specific receptor has been identified for sactibiotics.
The model, subtilosin A, can partly bury in the membrane of
target cells, causing a disorder in the hydrophobic region of
the membranes creating transient pores (Noll et al. 2011). On
the other hand, thurincin H does not appear to affect the mem-
brane permeability (Wang et al. 2014).
The common features in the sactibiotic gene clusters are the
presence of the structural gene(s), immunity proteins, trans-
porters, and S-adenosylmethionine enzymes containing a typ-
ical [4S-4Fe] conserved region (Fig. 2) (Flühe et al. 2013).
Class Id. Or linear azol(in)e-containing peptides
Linear azol(in)e-containing peptides (LAPs) are peptides
possessing various combinations of heterocyclic rings of thi-
azole and (methyl)oxazole, which are derived from cysteine,
serine, and threonine residues via ATP-dependent
cyclodehydration and subsequent flavin mononucleotide-
dependent dehydrogenation (Melby et al. 2011). The most
relevant LAB-produced LAP is streptolysin S (Fig. 1) (Cox
et al. 2015). Streptolysin S is modified by the cyclodehy
dratase SagCD. Recently, the SagD-homolog YcaO was
shown to be an ATP-dependent enzyme that phosphorylates
the amide backbone, although the function of the SacC homo-
log was not clear (Dunbar et al. 2012). Often, the SagCD
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analogs in other gene clusters are fused as a single protein.
Additionally, the synthesis of streptolysin S requires the dehy-
drogenase SagB, the protease SagE, the ABC transporter
SagGHI, and SagF, probably related with immunity (Lee
et al. 2008). The whole set cluster is controlled by a single
promoter with a rho-independent terminator behind the struc-
tural gene sagA (Fig. 2) (Nizet et al. 2000). Additional modifi-
cations have been found in other LAP clusters (Lee et al. 2008).
The mechanism of action of LAPs is unclear yet. Microcin
B17, from Escherichia coli, can inhibit bacterial gyrase under
certain conditions in a mechanism similar to quinolones
(Heddle et al. 2001).
Class Ie. Or glycocins
Glycocins are bacteriocins containing glycosylated residue(s)
(Arnison et al. 2013). Glycocin F from Lactobacillus
plantarum was the first glycocin described in LAB (Stepper
et al. 2011). Glycocin F is arranged as two alpha helices held
together by disulfide bonds (Venugopal et al. 2011). It pos-
sesses an N-acetylglucosamineβ-O-linked to serine and anN-
acetylhexosamine S-linked to the C-terminal cysteine, a very
infrequent type of glycosylation (Stepper et al. 2011). Little is
known about the mechanism of action of glycocins. The O-
linked N-acetylglucosamine could interact reversibly with tar-
get cells (Stepper et al. 2011). Apart from glycocin F,
enterocin F4-9 from Enterococcus faecium has also been de-
scribed (Fig. 1) (Maky et al. 2015). The biosynthetic gene
cluster of enterocin F4-9 consists of five genes (Fig. 2): enfT,
a putative ABC-transporter; the structural gene enfA49; the
glycosyltransferase enfC; and enfB and enfI, which resemble
a thioldisulfide isomerase and an immunity protein, respec-
tively (Maky et al. 2015). Unlike glycocin F, enterocin F4-9 is
assumed to be bacteriostatic (Maky et al. 2015).
Class If. Or lasso peptides
Lasso peptides are a group of RiPPs that show as a main
characteristic the presence of an amide bond between the first
amino acid in the core peptide chain and a negatively charged
residue in positions +7 to +9 generating a ring that embraces
the C-terminal linear part of the polypeptide (Fig. 1) (Arnison
et al. 2013; Hegemann et al. 2015). Moreover, lasso peptides
display diverse activities which range from antimicrobial to
putative antiviral or anticancer (Maksimov et al. 2012).
Additional modifications might be naturally present in lasso
peptides (Hegemann et al. 2015). Up to date, no lasso peptide
from LAB has been reported, but a few are predicted to occur
in streptococci (Table 1) (Table S1).
The first antimicrobial lasso peptide characterized was
microcin J25, produced by E. coli (Fig. 1). A cluster of four
genes is required for the production of microcin J25, namely,
the structural gene mcjA, the immunity determinant mcjD, the
leader peptidase mcjB, and the cyclase mcjC (Fig. 2) (Yan
et al. 2012). Microcin J25 uses the siderophore transporter
FhuA to enter the cell where it acts as a selective transcription
inhibitor able to temporarily block the RNA elongation by the
RNA polymerase (Mathavan et al. 2014). Additionally,
microcin J25 induces the generation of reactive oxygen spe-
cies that contribute to the inhibition mechanism (Chalon et al.
2009). Similarly, capistruin is a transcription inhibitor
(Kuznedelov et al. 2011) whereas lassomycin is a protease
inhibitor that targets Mycobacterium tuberculosis (Gavrish
et al. 2014).
One of the main interests of lasso peptides is their use as
peptide scaffolds due to their high stability. Diverse peptide
sequences with additional functionalities or even unnatural
amino acids can be displayed in lasso peptides (Piscotta
et al. 2015; Hegemann et al. 2015).
Class II: unmodified bacteriocins
Class IIa. Or pediocin-like bacteriocins
The pediocin-like class IIa bacteriocins are broad spectrum
antimicrobials particularly active agains Listeria (Kjos
et al. 2011). The structure of peptides of class IIa can be
divided in two different regions separated by a flexible
hinge (Haugen et al. 2008). The cationic N-terminal half
contains two cysteine residues joined by a disulfide bridge,
and a conserved YGNGVXC motif, which has been sug-
gested to participate in target interaction (Cui et al. 2012).
The replacement of this disulfide bridge by hydrophobic
interaction can still retain the activity (Sit et al. 2012). The
C-terminus is less conserved and seems to be involved in
the target cell specificity (Cui et al. 2012).
Class IIa bacteriocins are subdivided into eight groups
on the basis of their primary structures (Nissen-Meyer
et al. 2009). However, the first and the most extensively
studied representative of this class is pediocin PA-1. The
gene cluster of pediocin PA-1, like most IIa bacteriocins,
is plasmid encoded (Ennahar et al. 1999). The pediocin
PA-1 operon contains four genes, namely, the structural
gene pedA; the immunity determinant pedB; and pedC
and pedD which encode an ABC transporter and the ac-
cessory protein (Fig. 2). The operon produces two differ-
ent transcripts; the smaller and most abundant corre-
sponds to the pedABC genes, while the second transcript
is larger and covers pedABCD (Nissen-Meyer et al. 2009;
Cui et al. 2012). The leader peptide serves as a recogni-
tion signal for the processing and the secretion of the
bacteriocin by a dedicated ABC transporter. In a few
cases, the bacteriocin is secreted by the sec-dependent
translocation system (De Kwaadsteniet et al. 2006).
Class IIa bacteriocins can be constitutively produced
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(e.g., pediocin PA-1) or regulated by a QS system (e.g.,
sakacin A) (Ennahar et al. 1999).
The mode of action of class IIa bacteriocins comprises
three basic steps: pediocin binds to the sugar transporter man-
nose phosphotransferase system (Man-PTS) receptors, inserts
into the cytoplasmic membrane, and finally forms the pore
complex (Diep et al. 2007).
Class IIb. Or two-peptide bacteriocins
Class IIb bacteriocins consist of two very different pep-
tides, and full activity requires the presence of both pep-
tides in about equal quantities (Nissen-Meyer et al. 2010).
In some cases, such as lactococcin G from L. lactis
(Nissen-Meyer et al. 1992), antimicrobial activity requires
the presence of both peptides. However, for others such as
thermophilin 13 from Streptococcus thermophilus
(Marciset et al. 1997), individual peptides manifest antimi-
crobial activity by themselves, although their combination
always increases the activity. Exceptionally in enterocin X,
this varies in function of the indicator strain (Hu et al.
2010). The peptides can be combined with a complemen-
tary peptide from a homologous two-peptide bacteriocin
(Oppegård et al. 2007).
Mode-of-action studies of lactococcin G propose that
the peptides form a membrane-penetrating helix-helix
structure that interacts with a receptor of the membrane
of sensitive bacteria (Rogne et al. 2008), causing mem-
brane leakage. Lactococcin G-resistant mutants produced
in the lab pointed at the UppP protein, a membrane pro-
tein involved in peptidoglycan synthesis, as the putative
receptor for lactococcin G and enterocin 1071 (Kjos
et al. 2014).
The class IIb bacteriocin production requires at least
five different genes, and they might be organized in either
one or two different operons. Lactococcin G contains two
structural genes codifying the pre-bacteriocins, an immu-
nity gene, a gene that encodes a dedicated ABC transport-
er, and a gene encoding an accessory protein whose func-
tion is still unclear; all of them are arranged in the same
operon (Fig. 2) (Oppegård et al. 2010). The structural
genes are always produced in equal quantities and found
next to each other in the same operon along with only one
immunity gene. This fact suggests that the peptides work
together as one unit (Nissen-Meyer et al. 2009; Rogne
et al. 2008). The production of class IIb bacteriocins is
transcriptionally regulated by a QS system of three com-
ponents, which involves an induction factor, a membrane-
associate protein histidine kinase, and response regulators.
Plantaricin A, for instance, is the inductor factor of two
two-peptide bacteriocins, plantaricin J/K and plantaricin
E/F, from L. plantarum C11 (Diep et al. 2003).
Class IIc. Or leaderless bacteriocins
Leaderless bacteriocins are unique as they are synthetized
without an N-terminal leader peptide, which usually functions
as a recognition sequence for secretion and modification and
maintains the bacteriocin inactive inside the producer cell (Liu
et al. 2011; Masuda et al. 2012).
One of the best studied and characterized leaderless bacte-
riocins is the plasmid-encoded two-peptide enterocin L50
from E. faecium L50 (Fig. 1) (Cintas et al. 1998). The gene
cluster of enterocin L50 encodes 13 open reading frame
(ORF) (Fig. 2), including the two structural genes in tandem,
some accessory proteins, and four genes highly homologous
to the second ABC transporter as-48EFGH, which partici-
pates in immunity (Franz et al. 2007). The lack of genes
encoding immunity proteins is a common feature among lead-
erless bacteriocins, and the self-immunity mechanism is there-
fore still unclear (Iwatani et al. 2012).
NMR research has shown that enterocins 7A and 7B are
highly homologous to enterocins L50A and L50B and, unlike
most linear bacteriocins such as EJ97 (Neira et al. 2010),
maintain a defined structure in aqueous conditions (Lohans
et al. 2013). Moreover, enterocins 7A and 7B share a structur-
al motif with the circular bacteriocins. Lacticin Q causesmem-
brane leakage without any specific membrane receptor
(Yoneyama et al. 2009a). Cationic lacticin Q binds to nega-
tively charged membranes by electrostatic interactions and
forms huge toroidal pores that cause leakage (Yoneyama
et al. 2009b). In spite of the lack of a docking molecule, the
mechanism is selective against several sensitive Gram-
positive bacteria due to accumulation of hydroxyl radicals as
activity-inducing factor (Li et al. 2013). On the contrary, a zinc-
dependent membrane metallopeptidase has been identified as
the docking molecule of the leaderless bacteriocin LsbB from
L. lactis subsp. lactis BGMN1-5 (Uzelac et al. 2013). Recently,
it has been described for the first time that the expression of
LsbB is regulated by a transcription terminator sequence
located downstream of the structural gen (Uzelac et al. 2015).
Class IId. Or non-pediocin-like, single-peptide
bacteriocins
Class IId is a heterogeneous group of unrelated single linear
peptide bacteriocins with different structures, mechanisms of
secretion, and manners of action such as lactococcin 972,
lactococcin A, and enterocin B (Franz et al. 2007).
Lactococcin 972 is a heat-sensitive pH-stable peptide ac-
tive against closely related lactococci species (Martínez et al.
1999). The NMR structure of lactococcin 972 has been recent-
ly determined (Turner et al. 2012). The gene cluster is located
in a plasmid and comprises the structural gene lcn972 and two
hypothetical genes which could encode a dedicated ABC
transporter involved in immunity (Fig. 2) (Campelo et al.
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2014). The mature protein is secreted via a sec-dependent
system. Two different transcripts are produced: one comprises
the whole operon, and the second corresponds to the structural
gene (Martínez et al. 1999). The mechanism of action in
lactococcin 972 is through the inhibition of the cell wall bio-
synthesis in lactococci by binding to the cell wall precursor
lipid II (Martínez et al. 2000).
Lactococcin A is a narrow spectrum bacteriocin produced
by strains of L. lactis (Holo et al. 1991). The biosynthesis of
lactococcin A involves four different genes: the structural
gene (lcnA), the immunity gene (lciA), and two genes (lcnC,
lcnD) that encode the dedicated ABC transporter system and
its accessory protein (Stoddard et al. 1992). The Man-PTS is
the target receptor of lactococcin A (Diep et al. 2007).
Class III
Class III bacteriocins are large-molecular-weight and heat-
labile antimicrobial proteins usually composed of different
domains. For instance, based on sequence analysis,
enterolysin A consists of an N-terminal endopeptidase domain
and a C-terminal substrate recognition domain similarly to
zoocin A (Nilsen et al. 2003; Lai et al. 2002). Zoocin A, a
D-alanyl-L-alanine endopeptidase, is one of the best-
characterized LAB bacteriolysins (Fig. 2) (Simmonds et al.
1996). It shows antimicrobial activity against other strep-
tococci by cleaving the peptidoglycan cross-links of the
target cell wall (Simmonds et al. 1996). The zif gene, close
to zooA, encodes an immunity protein which adds L-ala-
nine into the peptidoglycan cross-bridges, thus decreasing
the ability of zoocin A to degrade the peptidoglycan layer
(Gargis et al. 2009).
Millericin B is a murein hydrolase. Its production depends
on the expression of three genes encoding millericin B pre-
cursor (MilB), immunity protein (MilF), and transporter pro-
tein (MilT) (Beukes et al. 2000). Similarly, enterolysin A
cleaves within the peptidoglycan of target cells between L-
alanine and D-glutamic acid of the stem peptide and between
L-lysine of the stem peptide and D-aspartic acid of the
interpeptide bridge (Khan et al. 2013).
On the other hand, non-lytic bacteriocins exhibit their bac-
tericidal mode without causing concomitant cell lysis. For
instance, dysgalacticin from S. pyogenes binds to the
glucose- and/or Man-PTS, resulting in the inhibition of the
sugar uptake, and also causes a membrane leakage of small
molecules (Swe et al. 2009). In contrast, caseicin from
Lactobacillus casei inhibits the biosynthesis of DNA and pro-
teins of target bacteria (Müller and Radler 1993). Little is
known about their genetics. The biosynthesis of helveticin J
from Lactobacillus helveticus 481 involves at least three ORF,
but their specific functions remain still unknown (Fig. 2)
(Joerger and Klaenhammer 1990).
Application in the food industry
Nowadays, consumers ask for safe, healthy, tasting, long
shelf-life, and minimally processed food products. LAB are
food-grademicroorganisms that have been extensively used in
fermented foods, and many of them have GRAS and QPS
status. As a result, bacteriocins and other metabolites pro-
duced by LAB are also generally considered as safe com-
pounds with interesting properties (e.g., stability, antimicrobi-
al activity, lack of toxicity, no flavor alteration) (Carr et al.
2002; Cotter et al. 2005). Until now, only nisin and pediocin
PA-1 have been commercialized as food additives. However,
other LAB bacteriocins also offer promising perspectives to
be used as biopreservatives in food, like for instance the
enterocin AS-48 (Sánchez-Hidalgo et al. 2011) or lacticin
3147 (Suda et al. 2012).
Bacteriocins can be added as bacteriocin preparations or by
direct inoculation of the bacteriocin-producing strain. The
bacteriocin preparation can be a purified or semi-purified bac-
teriocin added as food preservative, such as nisin which is
commonly exploited under the name of Nisaplin™
(Danisco, E234) (Cotter et al. 2005). In fact, nisin is the only
bacteriocin licensed as biopreservative in over 50 countries.
Bacteriocins can also be added in the form of concentrated
fermentate generated from a bacteriocin-producing strain.
For instance, ALTA 2431™ (Quest) is a fermentation product
from a pediocin PA-1-producing strain (Rodríguez et al.
2002). Bacteriocinogenic strains can be as well directly inoc-
ulated into the food as starter, adjunct, or protective cultures.
Actually, LAB and, therefore, their bacteriocins, have been
empirically applied as starter cultures in the production of
traditional foods (Leroy et al. 2006; Alegría et al. 2010).
Recently, bacteriocins have also been incorporated into pack-
aging films to control food-borne pathogenic bacteria ensur-
ing a gradual release of bacteriocins into the food and avoiding
the inactivation of the bacteriocin by interaction with food
components (Guerra et al. 2005). Furthermore, several studies
have shown that bacteriocin antimicrobial activity is enhanced
against Gram-negative bacteria when combined with physico-
chemical treatments (hurdle technology) such as high pressure
(Pérez Pulido et al. 2015), organic acids (Ukuku and Fett
2004), phenolic compounds (Grande et al. 2007), and pulsed
electric fields (Martínez Viedma et al. 2008).
Enhancement of probiotic action
Many LAB strains are proposed as probiotics, i.e., live micro-
organisms which, when administered in adequate amounts,
confer a health benefit on the host (FAO/WHO 2001). In re-
cent years, several in vitro and in vivo studies have shown that
LAB bacteriocins exhibit a protective effect in the gastrointes-
tinal tract (GIT) by excluding pathogens or promoting gut
colonization (Corr et al. 2007; Dobson et al. 2012;
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Kommineni et al. 2015). For instance, the antilisterial Abp118
from Lactobacillus salivarius UCC118 protects mice against
infection with the pathogen L. monocytogenes (Corr et al.
2007), and the S. mutans BCS3-L1 strain is able to replace
existing S. mutans populations and persist over time in the oral
cavity, due to the advantage conferred by its bacteriocin,
mutacin 1140 (Hillman et al. 2000). Furthermore,
Kominneni et al. (2015) proved that niche competition in the
GIT is directly influenced by bacteriocin expression by com-
mensal bacteria.
Gastrointestinal infections are a major concern in human
health, but antibiotics cause a harmful effect on gut microbi-
ota. Therefore, the anti-infective effect of LAB-producing
bacteriocins is a promising alternative to antibiotics, especial-
ly for particular cases where other methods are not allowed
(e.g., pregnant women) (Hammami et al. 2013).
Concluding remarks
The concomitant application of bacteriocin-producer
LAB or (semi)purified bacteriocins, together with the ap-
plication of other physicochemical treatments, constitutes
an effective method of natural biopreservation in food
industry and enables the reduction of other costly or
user-unfriendly treatments, while increasing the product
self-life.
The discovery of the gene clusters encoding for RiPPs
that were previously thought to be non-ribosomally pro-
duced but assembled by multimeric enzymatic complexes
demonstrates the huge chemical diversity that can be
achieved in natural products by the sequential modification
of a peptide substrate by specific PTMs. This chemical
diversity is related to different properties (i.e., antimicro-
bial spectrum, stability, potency). The conserved motifs in
the PTMs and the core peptides facilitate the high-
throughput analysis of (meta)genomic data which can help
focus the screening efforts to discover new molecules
using diverse alternatives (Montalbán-López et al. 2012b;
Hegemann et al. 2015; Rutledge and Challis 2015). In ad-
dition to the three bacteriocin classes proposed in the early
1990s (Klaenhammer 1993), our broad genome mining
analysis of LAB shows that the repertoire of antimicrobials
that are encoded in public sequences could be even broader
than expected, with some putative classes not reported so
far in LAB (i.e., lasso peptides and sactipeptides), opening
up a wide range of possibilities for future applications.
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